Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Enseleit, F; Michels, S; Ruschitzka, F (2010). Anti-VEGF therapies and blood pressure: more than meets the eye. Current Hypertension Reports, 12(1):33-38.

Full text not available from this repository.

Abstract

"Wet" (also called neovascular) age-related macular degeneration (AMD) is a chronic progressive disease characterized by leakage of fluid or blood from choroidal neovascularization. It remains the leading cause of blindness in the developed world. Vascular endothelial growth factor (VEGF), which plays a key role in the pathogenesis of retinal neovascularization and vessel leakage leading to central vision loss, has emerged as a potential target in the treatment of wet AMD. Importantly, large-scale clinical trials have demonstrated that intravitreal VEGF antagonism prevents vision loss and may even improve visual acuity in patients with neovascular AMD. Because VEGF and its downstream mediator nitric oxide have a well-established cardioprotective role, however, it can be argued that the beneficial effects of VEGF antagonism in the eye may come at the cost of adverse systemic effects, particularly myocardial infarction and stroke.

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
DDC:610 Medicine & health
Language:English
Date:2010
Deposited On:14 Dec 2010 13:09
Last Modified:28 Nov 2013 01:07
Publisher:Springer
ISSN:1522-6417
Publisher DOI:10.1007/s11906-009-0082-x
PubMed ID:20425156
Citations:Web of Science®. Times Cited: 6
Google Scholar™

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page